Evidence map›Paper›PMID 42033283›Full record

SynthesisPacing and clinical electrophysiology : PACE2026

Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis.

Abdalhakim Shubietah, Mohamed S Elgendy, Ameer Awashra, Mohamed R Murad, Mohammad Alqudah, Ibrahim Gowaily, Ahmed Almahdy Mohamed, Ahmed Emara, Emmanuel Olumuyide, Ahmed Elbataa and 2 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdalhakim ShubietahDepartment of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-8300-0262
Mohamed S ElgendyFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID https://orcid.org/0000-0003-3080-2875
Ameer AwashraDepartment of Medicine, An-Najah National University, Nablus, Palestine.ORCID https://orcid.org/0009-0002-5122-8200
Mohamed R MuradFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohammad AlqudahFaculty of Medicine, Yarmouk University, Irbid, Jordan.ORCID https://orcid.org/0000-0001-6645-1830
Ibrahim GowailyDepartment of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.
Ahmed Almahdy MohamedDepartment of Cardiology, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.
Ahmed EmaraFaculty of Medicine, Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0009-0001-2718-8627
Emmanuel OlumuyideDepartment of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.
Ahmed ElbataaFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed AbuelazmFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID https://orcid.org/0000-0002-2514-0689
Mohammed MhannaDivision of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa, USA.ORCID https://orcid.org/0000-0003-1443-7177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong patients undergoing catheter ablation for atrial fibrillation (AF), it remains uncertain whether peri- or post-ablation use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduces AF recurrence.

objectivesWe conducted a meta-analysis of observational studies and randomized controlled trials comparing GLP-1 RA therapy versus no GLP-1 RA use on AF recurrence following ablation.

methodsWe systematically searched PubMed, Scopus, Web of Science, and Embase for adult randomized and observational studies. Random-effects models generated risk ratios (RRs), and heterogeneity was assessed via I

resultsSix studies met the inclusion criteria, with four contributing data for Kaplan-Meier curve reconstruction and five included in the hazard ratio (HR) meta-analysis. Across four studies (n = 695; GLP-1 RA = 295; control = 400), pooled Kaplan-Meier curves showed a lower risk of AF recurrence with GLP-1 RA therapy (HR 0.53, 95% confidence interval [CI]: 0.38-0.72), with a restricted mean survival time (RMST) advantage of 1.02 months. A random-effects meta-analysis of five studies confirmed this benefit (HR 0.78, 95% CI: 0.61-0.99; I

conclusionGLP-1 RA therapy was associated with reduced AF recurrence after ablation, but methodological limitations warrant cautious interpretation. Prospective randomized trials are needed to confirm this potential benefit.

Indexed as

Atrial FibrillationCatheter AblationGlucagon-Like Peptide-1 Receptor AgonistsHumansRandomized Controlled Trials as TopicRecurrenceTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsAF recurrenceatrial fibrillationcatheter ablationGLP‐1 receptor agonistspost‐ablation therapy

Identifiers

PMID42033283
PMCPMC13456437

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.